Core Scientific, Inc.

As of June 30, 2026, Core Scientific Inc carries a market capitalization of 7.15B, placing it among publicly traded companies globally. Its enterprise value stands at 9.37B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Core Scientific Inc's next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Core Scientific Inc has 319.59M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 18.68, and the price-to-book ratio stands at -3.38.

These figures are as of June 30, 2026. The EV/Sales ratio of 24.30 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 9.37B versus a market cap of 7.15B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Core Scientific Inc maintains a current ratio of 0.89, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -177.65, indicating conservative leverage, while an interest coverage ratio of -103.95 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -39.59, reflecting losses generated across the asset base. The company generates approximately 1.19M in revenue per employee across its workforce of 325.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Core Scientific Inc recorded 2.39M in income tax expense. The company reported a pretax loss of -1.25B and -1.25B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Core Scientific Inc's stock has declined approximately 23.82% over the past 52 weeks. The 50-day moving average sits at 14.60, while the 200-day moving average is 17.08.

Over the twelve months ended June 30, 2026, Core Scientific Inc generated 385.40M in revenue and converted that into -1.25B in net income, yielding earnings per share of -3.50. EBITDA reached -441.92M, while operating income came in at -180.22M.

As of June 30, 2026, Core Scientific Inc holds 1.55B in cash and equivalents against 3.76B in total debt, resulting in a net debt position of 2.21B. Total book value stands at -2.12B, with working capital of -257.47M providing operational flexibility.

Core Scientific Inc produced 451.48M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.30B in capital expenditures, free cash flow totaled -847.27M - equivalent to -2.63 per share.

Over the twelve months ended June 30, 2026, Core Scientific Inc posted a gross margin of 28.35, reflecting its pricing power and cost economics. The operating margin of -46.76 and net profit margin of -325.31 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -10.58: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -38.72, meaning Core Scientific Inc raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Core Scientific Inc has an Altman Z-Score of -1.05, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.